Immunotherapeutic approach on triple negative breast cancer: recent progress and predictors of response

作     者：Louis Wing-Cheong Chow Erich Ferdiansyah Lie Louis Wing-­Cheong Chow;Erich Ferdiansyah Lie

作者机构：UNIMED Medical InstituteHong KongChina Organisation for Oncology and Translational ResearchHong KongChina 

出 版 物：《中华乳腺病杂志（电子版）》 (Chinese Journal of Breast Disease(Electronic Edition))

年 卷 期：2022年第16卷第4期

页      面：199-203页

学科分类：1002[医学-临床医学] 100214[医学-肿瘤学] 10[医学] 

主　　题：Triple negative breast cancer Immunotherapy Microenvironment 

摘      要：Clinical trials utilizing the immune checkpoint inhibitors,particularly the IMpassion and KEYNOTE trials,have made it possible to understand how the immune checkpoint inhibitors can be used to treat patients with triple negative breast cancer(TNBC).Patient stratification based on simply PD-L1 positivity has now been shown to be insufficient and inaccurate as a predictor of response to the immune checkpoint inhibitors,and the role of the tumor microenvironment has become more *** article serves as a brief overview of the latest progress on the clinical trials as well as the potential predictors of response to immune checkpoint blockade.